RecruitingPhase 3NCT06609226
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Studying Thalassemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novo Nordisk A/S
- Principal Investigator
- Clinical Transparency (dept. 2834)Novo Nordisk A/S
- Intervention
- Etavopivat A(drug)
- Enrollment
- 480 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2025 – 2030
Study locations (30)
- Univ of Alabama Birmingham, Birmingham, Alabama, United States
- Phoenix Children's Hsptl, Phoenix, Arizona, United States
- Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
- UCSF Oakland Benioff ChildHosp, Oakland, California, United States
- Children's Hosp Of Orange, Orange, California, United States
- University Of California Irvine, Orange, California, United States
- University of Connecticut, Farmington, Connecticut, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Foundation for Sickle Cell Disease Research, Hollywood, Florida, United States
- Univ of Miami/SCCC, Miami, Florida, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Children's Healthcare Atlanta, Atlanta, Georgia, United States
- Center for Blood Disorders Augusta University, Augusta, Georgia, United States
- Univer Of Illinois at Chicago, Chicago, Illinois, United States
- Children's Hosp-New Orleans, New Orleans, Louisiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06609226 on ClinicalTrials.govOther trials for Thalassemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07338344Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT PatientsRongrong Liu
- RECRUITINGNANCT07112703Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia MajorRawan Mohammed Khairy Mostafa Elsawy
- RECRUITINGNANCT06931912Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With ThalassemiaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06657391Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent ThalassemiaRongrong Liu
- ENROLLING BY INVITATIONNCT07003269Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCTHaikou Affiliated Hospital of Central South University Xiangya School of Medicine
- ACTIVE NOT RECRUITINGNCT06596642A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in TaiwanBristol-Myers Squibb
- RECRUITINGPHASE1NCT06655662Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.Shenzhen Hemogen
- RECRUITINGPHASE2NCT06302491A Study of Safety and Efficiency of AND017 in Patients With β-thalassemiaKind Pharmaceuticals LLC